Merck (MRK) Net Income (2009 - 2026)
Merck (MRK) posted quarterly Net Income of -$4.2 billion for Q1 2026, down 182.77% YoY from $5.1 billion in Q1 2025, and down 242.1% sequentially from $3.0 billion in Q4 2025.
Merck (MRK) Net Income (2009 - 2026) Analysis & Trends
Merck has disclosed Net Income across 17 years of filings, most recently posting -$4.2 billion for Q1 2026.
- In Q1 2026, Net Income fell 182.77% year-over-year to -$4.2 billion; the TTM figure through Mar 2026 stood at $9.0 billion (down 48.61% YoY), while the FY2025 annual figure was $18.3 billion, up 6.6% from the prior year.
- Net Income declined to -$4.2 billion in Q1 2026, from $3.0 billion in the prior quarter.
- Over the last five years, Net Income for MRK reached as high as $5.8 billion in Q3 2025 and fell as low as -$5.9 billion in Q2 2023.
- The 4-year median for Net Income is $3.7 billion (2024), against an average of $2.4 billion.
- Annual changes were most pronounced in 2024 — Net Income soared 405.38% — and 2026, when it plunged 182.77%.
- A 4-year view of Net Income shows it stood at -$1.2 billion in 2023, then soared by 405.38% to $3.7 billion in 2024, then decreased by 20.89% to $3.0 billion in 2025, then slumped by 242.1% to -$4.2 billion in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$4.2 billion, $3.0 billion, and $5.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.40 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 5.24 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 697.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 833.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -13.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 319.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.21 Bn |
| Dec 31, 2025 | 2.96 Bn |
| Sep 30, 2025 | 5.79 Bn |
| Jun 30, 2025 | 4.43 Bn |
| Mar 31, 2025 | 5.09 Bn |
| Dec 31, 2024 | 3.74 Bn |
| Sep 30, 2024 | 3.16 Bn |
| Jun 30, 2024 | 5.46 Bn |
| Mar 31, 2024 | 4.77 Bn |
| Dec 31, 2023 | -1.23 Bn |
| Sep 30, 2023 | 4.75 Bn |
| Jun 30, 2023 | -5.94 Bn |
| Mar 31, 2023 | 2.83 Bn |
| Dec 31, 2021 | -62.00 Mn |
| Jun 30, 2021 | 332.00 Mn |
| Mar 31, 2021 | 437.00 Mn |
| Dec 31, 2020 | 523.00 Mn |
| Sep 30, 2020 | 617.00 Mn |
| Jun 30, 2020 | 661.00 Mn |
| Mar 31, 2020 | 3.22 Bn |